This company listing is no longer active
71M Stock Overview
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Myovant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.19 |
| 52 Week High | €27.11 |
| 52 Week Low | €7.29 |
| Beta | 2.15 |
| 1 Month Change | 1.90% |
| 3 Month Change | 0.32% |
| 1 Year Change | 137.87% |
| 3 Year Change | 319.83% |
| 5 Year Change | 70.90% |
| Change since IPO | 129.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 71M | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | -1.4% | -0.9% |
| 1Y | 137.9% | -12.5% | 14.1% |
Return vs Industry: 71M exceeded the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 71M exceeded the German Market which returned -5.6% over the past year.
Price Volatility
| 71M volatility | |
|---|---|
| 71M Average Weekly Movement | 1.9% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 71M has not had significant price volatility in the past 3 months.
Volatility Over Time: 71M's weekly volatility has decreased from 11% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 579 | Dave Marek | myovant.com |
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction.
Myovant Sciences Ltd. Fundamentals Summary
| 71M fundamental statistics | |
|---|---|
| Market cap | €2.62b |
| Earnings (TTM) | -€172.71m |
| Revenue (TTM) | €356.29m |
Is 71M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 71M income statement (TTM) | |
|---|---|
| Revenue | US$379.11m |
| Cost of Revenue | US$209.66m |
| Gross Profit | US$169.45m |
| Other Expenses | US$353.22m |
| Earnings | -US$183.77m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.89 |
| Gross Margin | 44.70% |
| Net Profit Margin | -48.47% |
| Debt/Equity Ratio | -64.3% |
How did 71M perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/13 01:02 |
| End of Day Share Price | 2023/03/09 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Myovant Sciences Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Mohit Bansal | Citigroup Inc |
| Jason Butler | Citizens JMP Securities, LLC |